Fundraising FoxImplican
3 known investors
Find your way into Implican
Sign up to see every warm intro you have to Implican
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Implican team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Implican is developing a patented anastomotic device that uses two compression rings to fixate bowel walls during colorectal surgery, aiming to achieve primary wound healing and reduce anastomotic leakage. The device targets surgeons treating colorectal cancer patients as an alternative to circular staplers, and is in preclinical/clinical testing.
Founders & leadership
RK
Rik KielmanChief Executive Officer (CEO)Rik Kielman previously held a commercial strategy role at Sensius, where he developed market access strategies for European and US clinics and directed reimbursement efforts, before joining Implican as CEO to oversee regulatory, clinical, and market strategy for the company's anastomotic fixation device.
IK
Investors · 3
NextGen Ventureslisted by NextGen VenturesEde
How we know: NextGen Ventures's portfolio page · Not right? Tell us
Nomreported
How we know: funding news · Not right? Tell us
Frequently asked questions
- What does Implican do?
- Implican is developing a patented anastomotic device that uses two compression rings to fixate bowel walls during colorectal surgery, aiming to achieve primary wound healing and reduce anastomotic leakage. The device targets surgeons treating colorectal cancer patients as an alternative to circular staplers, and is in preclinical/clinical testing.
- Who are Implican's investors?
- Implican's investors include NextGen Ventures, NV NOM, Nom.